John van Duzer
John van Duzer, Ph.D., is VP, CMC at Acrivon Therapeutics, Inc. John is a senior pharmaceutical industry executive with over 30 years of proven expertise in medicinal chemistry research, chemical development and GMP manufacturing of both active pharmaceutical ingredients and drug products. Prior to Acrivon, he was the SVP of Chemistry and Manufacturing at Acetylon. John is the inventor of Ricolinostat and Citarisnostat, selective HDAC6 inhibitors studied in the clinic for the treatment of multiple myeloma. When Celgene acquired Acetylon, he led the CMC tech transfer team that integrated Acetylon’s manufacturing processes into Celgene. Previously, while at Novartis, he invented Lumarcoxib, a marketed selective COX-2 inhibitor. At Eloxx Pharmaceuticals, he was the VP of Technical Operations responsible for all aspects of chemical development. He also served as the VP of Pharmaceutical Development and Manufacturing at Collegium Pharmaceuticals where he oversaw tech transfer of the commercial product Nucynta to a new manufacturing site. He is also the co-inventor of 36 patents and has co-authored 18 peer-reviewed scientific papers. John received his Ph.D. in Synthetic Organic Chemistry from Yale University, and B.A. in Chemistry from the University of Pennsylvania.